摘要:
Substituted nicotinamide compounds corresponding to formula I a process for their preparation, pharmaceutical compositions containing these compounds, and the use thereof for the treatment or inhibition conditions such as pain, epilepsy, migraine, anxiety states, or urinary incontinence.
摘要:
The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.
摘要:
The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.
摘要:
Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
摘要:
Substituted tetrahydropyrrolopyrazine compounds corresponding to formula I a process for producing such compounds; and a method of using such compounds to treat or inhibit various disorders or disease states including pain, depression and anxiety.
摘要:
Substituted tetrahydropyrrolopyrazine compounds corresponding to formula I a process for producing such compounds; and a method of using such compounds to treat or inhibit various disorders or disease states including pain, depression and anxiety.
摘要:
The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.
摘要:
Vanilloid receptor ligand compounds corresponding to formula I: a process for producing such compounds, pharmaceutical compositions containing them, and the use of such compounds to treat pain and various other vanilloid receptor mediated conditions.
摘要:
A method for identifying the agonistic activity of a target compound on a potassium channel by a) providing a population of cells expressing a potassium channel and, optionally providing, a protein-based fluorescent-optical voltage sensor, b) if necessary, incubating the cells with a voltage-sensitive fluorescent dye, c) adding the target compound to the reaction batch of a) or b), d) determining a value F1 of the fluorescence intensity of the cells, e) adding potassium ions in a physiologically acceptable concentration f) determining a value F2 of the fluorescence intensity of the cells, and g) comparing the fluorescence intensity F2 with the fluorescence intensity F1 and determining the agonistic activity of the target compound on a potassium channel therefrom. A potassium channel agonist isolated and purified by this method, pharmaceutical formulations containing the same, and their use for the treatment of a disease in which potassium channels are involved.
摘要:
Substituted benzo[d]isoxazol-3-yl amine compounds corresponding to formula I which exhibit an strong affinity to the KCNQ2/3 K+ channel, and which are suitable for treating or inhibiting pain and/or disorders or disease states that are at least partly mediated by the KCNQ2/3 K+ channel.